Therapy of acute and chronic gram-negative @entity4034 with XXXX . Report from a Swedish Study Group.

@entity1 @entity1712 @entity227 @entity6337 @entity796 @entity625 @entity1910 @entity4034 @entity2177 @entity794 @entity797 @entity1897 @entity4432 @entity490 @entity221
Oral @entity2177 was used at doses ranging from 500 mg to 1500 mg twice daily for 15 to 476 (mean 139) days for treatment of @entity4432 in 38 @entity1 , and acute @entity625 in two. Clinical efficacy could be evaluated in 34 @entity1 ; 22 had resolution of their @entity4034 , five improved and there were seven failures. @entity796 was the causative agent in 28 @entity1 . It was eradicated in 22 @entity1 , persisted but remained sensitive to @entity2177 in three and persisted with emergence of resistance to @entity2177 in three. Nineteen other pathogens, five Gram-negative and 14 Gram-positive, were isolated. Of those, one strain of @entity794 , two of Staph. epidermidis and three of @entity797 remained sensitive to @entity2177 during treatment. In one @entity1 , Slr. faecalis persisted with emergence of resistance to @entity2177 . Ten adverse events related to @entity2177 treatment were observed in nine @entity1 ; two @entity6337 , two cases of @entity227 , and one each of @entity1910 , @entity490 , malaise, @entity221 , @entity1897 and @entity1712 . In three @entity1 the adverse events led to treatment discontinuation. In conclusion, @entity2177 seems to offer an oral alternative to injectible antibiotics in @entity1 with @entity4034 caused by Gram-negative bacteria, including Ps. aeruginosa.
